论文部分内容阅读
目的检测DLEC1(deleted in lung and esophageal cancer1)基因在结直肠癌(colorectal cancer,CRC)患者组织和血清中的甲基化状态,分析其临床意义。方法留取71例CRC患者癌组织、相应正常组织及术前血清标本,20例肠道良性病变及20例健康志愿者血清标本,甲基化特异性聚合酶链反应(MSP)检测DLEC1基因启动子区域甲基化情况。结果 71例CRC组织中,DLEC1基因启动子甲基化比例为45.1%(32/71),而正常组织为7.1%(4/56),差异有统计学意义(P<0.001);DLEC1基因启动子甲基化与患者临床病理特征及CEA、CA19-9水平之间无相关性。相应CRC血清DNA中DLEC1甲基化比例为39.4%(28/71),而对照组为2.5%(1/40),差异有统计学意义(P<0.001),且血清DNA甲基化状况与组织中具有良好的一致性。结论 DLEC1基因启动子甲基化在CRC患者中有着较高的检出率,可望成为CRC辅助诊断的新型分子标记。
Objective To detect the methylation status of the deleted in lung and esophageal cancer1 gene in the tissue and serum of patients with colorectal cancer (CRC) and analyze its clinical significance. Methods Totally 71 serum samples from CRC patients, corresponding normal tissues and preoperative serum samples, 20 intestinal benign lesions and 20 healthy volunteers were collected. The methylation-specific polymerase chain reaction (MSP) was used to detect the activation of DLEC1 gene Sub-regional methylation. Results The DLEC1 promoter methylation was 45.1% (32/71) in normal CRC tissues and 7.1% (4/56) in normal CRC tissues. The difference was statistically significant (P <0.001). DLEC1 gene promoter There was no correlation between sub-methylation and clinicopathological features and CEA, CA19-9 levels. The methylation of DLEC1 was 39.4% (28/71) in the corresponding CRC serum DNA and 2.5% (1/40) in the control group, the difference was statistically significant (P <0.001) The organization has good consistency. Conclusion DLEC1 gene promoter methylation has a high detection rate in CRC patients and is expected to become a new molecular marker for CRC diagnosis.